{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:26:18Z","timestamp":1787066778189,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032702","name":"Genmab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bneo.2025.100080","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:30:00Z","timestamp":1740141000000},"page":"100080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savreet","family":"Bains Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Arnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rivas Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blaedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2025.100080_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of follicular lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.bneo.2025.100080_bib2","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.bneo.2025.100080_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100080_bib4","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bneo.2025.100080_bib5","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1016\/j.clml.2022.06.014","article-title":"The impact of sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis","volume":"22","author":"Xie","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.bneo.2025.100080_bib6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100080_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2025.100080_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000745","article-title":"A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)","volume":"6","author":"Salles","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.bneo.2025.100080_bib9","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100080_bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-020-04345-3","volume":"100","author":"Zettl","year":"2021","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100080_bib11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100080_bib13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100080_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100080_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00598-x","article-title":"Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9873","key":"10.1016\/j.bneo.2025.100080_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.bneo.2025.100080_bib17","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100080_bib18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bneo.2025.100080_bib19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100080_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2025.100080_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/fon-2019-0660","article-title":"Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients","volume":"16","author":"Albarmawi","year":"2020","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100080_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjh.13399","article-title":"Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States","volume":"170","author":"Nabhan","year":"2015","journal-title":"Br J Haematol"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100080_bib23","article-title":"Treatment patterns among elderly follicular lymphoma patients diagnosed between 2000 and 2011: an analysis of linked SEER-Medicare data [abstract 7563]","volume":"35","author":"Onukwugha","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2025.100080_bib24","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100080_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bneo.2025.100080_bib26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.bneo.2025.100080_bib27","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100080_bib28","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bneo.2025.100080_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100080_bib30","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood-2021-146182","article-title":"Trial-in-progress: randomized phase II trial in early relapsing or refractory follicular lymphoma (NCT#03269669): SWOG S1608 [abstract]","volume":"138","author":"Barr","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100080_bib31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.31821","article-title":"Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes","volume":"125","author":"Hester","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bneo.2025.100080_bib32","doi-asserted-by":"crossref","first-page":"978391","DOI":"10.1155\/2012\/978391","article-title":"Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare","volume":"2012","author":"Griffiths","year":"2012","journal-title":"J Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100080_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jclinepi.2013.08.013","article-title":"Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus","volume":"67","author":"Li","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100080_bib34","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/j.clml.2022.02.003","article-title":"Age differences in clinical trial understanding in non-Hodgkin lymphoma patients","volume":"22","author":"Luan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:56:38Z","timestamp":1762894598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2950328025000159"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100080","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100080"}}